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The disease burden related to diabetes is high and rising in every country,
fuelled by the global rise in the prevalence of obesity and unhealthy life-
styles. The latest estimates show a global prevalence of 382 million peo-
ple with diabetes in 2013, expected to rise to 592 million by 2035. The
aetiological classification of diabetes has now been widely accepted.
Type 1 and type 2 diabetes are the two main types, with type 2 diabetes
accounting for the majority (>85%) of total diabetes prevalence. Both
forms of diabetes can lead to multisystem complications of microvascular
endpoints, including retinopathy, nephropathy and neuropathy, and
macrovascular endpoints including ischaemic heart disease, stroke and
peripheral vascular disease. The premature morbidity, mortality, reduced
life expectancy and financial and other costs of diabetes make it an
important public health condition.
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Type 1 diabetes
The acute onset of type 1 diabetes mellitus and its rapid pre-
sentation to medical attention facilitates accurate registering of
new cases. Provided ascertainment can be verified, these data
can be combined with population denominator data to give age-
specific and sex-specific incidences.Geographical variationThe incidence of type 1 diabetes in children varies nearly 400-
fold between countries (Figure 1) with age-adjusted incidence
rates ranging from 0.1 per 100,000 per year in parts of Venezuela
and China to 37.8 in Sardinia and 40.9 per 100,000/year in
Finland.1 The high rate observed in Sardinia is notably discor-
dant with the incidence in Italy as a whole. Incidence also varies
within several other countries including China, where there is a
12-fold variation by region (0.13e1.61/100,000). In general,
countries in Europe and North America have either high or
intermediate incidences. The incidence in Africa is generally in-
termediate and that in Asia is low, with the notable exception of
Kuwait.Variation with age, sex, and ethnicityType 1 diabetes can occur at any age, but in most populations the
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up to around 10e15 years. There are no population-based inci-
dence data for ages above 35 years. Overall, there is a slight male
excess among children in high-incidence countries, while the
opposite is seen in low-incidence countries, but these differences
are small.1 However, there is generally a male excess among
young adults,2 and peak incidence is around puberty in most
populations. Mirroring the geographic pattern, incidence is higher
in populations of European origin than in non-Europeans.1Temporal variationAverage increases of 2.8e3.0% per year worldwide1 and of 3.9%
per year in Europe 3 have been reported. Generally, the relative
magnitude of increase is greater in low-incidence countries. The
most pronounced increase is in the youngest age group (0e4
years).1,3 The incidence of type 1 diabetes also varies with sea-
son, being highest in autumn and winter.4Aetiological factorsGenetic susceptibility is important but not sufficient in causation
of type 1 diabetes. Environmental factors have a more important
role in progression from islet autoimmunity to overt disease,
possibly because improved living standards have reduced
microorganism exposure, leading to increased autoimmunity.
Case-control studies have shown associations with early social
mixing, viral infections, toxins and dietary factors such as exclu-
sive breast-feeding and delayed introduction of cows’ milk. Hy-
pothesized aetiological factors include a vitamin D deficiency,5
which has been implicated by some genetics studies.6 Sugges-
tions for a role of omega-3 fatty acids have also been made.7
Type 2 diabetes
The slow onset of type 2 diabetes, and its usual presentation
without the acute metabolic disturbance seen in type 1 diabetes,
means that the true time of onset is difficult to determine. There
is also a long pre-detection period, and up to one-half of cases in
the population may be undiagnosed.Diagnosis of type 2 diabetesBecause the ratio of detected to undetected cases may vary over
time and between places, epidemiological research aimed at
defining the true prevalence of type 2 diabetes has relied on special
studies in which the presence and absence of disease are defined
by the oral glucose tolerance test (OGTT). TheWHO recommends
use of the 75 g OGTT, with diabetes defined by fasting glucose 7.0
mmol/L or more and/or 2-hour post-challenge glucose 11.1
mmol/L or more. Recently, the American Diabetes Association,
the WHO and other authoritative bodies have approved the use of
HbA1c for the diagnosis of diabetes with a cut-off of 48 mmol/mol
(>6.5%) in a standardized laboratory.Variation in prevalence by geographical location, ethnicity,
age, and sexFigure 2 shows the age-standardized prevalence of type 2 dia-
betes and impaired glucose tolerance (IGT). As in type 1 dia-
betes, there is marked geographical variation, but the pattern is
different. The prevalence is lowest in rural areas of developing
countries, generally intermediate in developed countries, and
highest in certain ethnic groups, particularly those that have 2014 The Authors. Published by Elsevier Ltd. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Figure 1
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MEDICINE 42:12 699adopted Western lifestyle patterns. Populations with the highest
prevalence have a high prevalence of obesity. It is hypothesized
that genetic susceptibility to obesity would be disadvantageous
in times of food abundance, but advantageous when food is
scarce, driving its persistence by natural selection. This ‘thrifty
genotype’ hypothesis is supported by evidence of gene
eenvironment interaction; individuals who migrate from low-
prevalence areas to the West are at increased risk of type 2 dia-
betes. Diabetes is up to fourfold to sixfold more prevalent in
South Asians and African-Caribbeans in the UK compared with
European white populations.8 There is only a small gender dif-
ference in the global numbers of people with diabetes, with about
14 million more men than women estimated to have diabetes in
2013.9 The prevalence increases sharply with age in both sexes.9 2014 The Authors. Published by Elsevier Ltd. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
DIABETES: BASIC FACTSIncidence and temporal variationFrom studies using serial glucose tolerance testing the annual
incidence in Europeans is around 7 per 1000 per year in Western
populations.10 The incidence in individuals known to have IGT is
about tenfold greater than in those with normal glucose toler-
ance.11 The risk of future progression to diabetes is also greater
in those with other hyperglycaemic states, including gestational
diabetes mellitus. Data from the US Centre for Disease Control
show a near quadrupling of diagnosed diabetes from 5.5 million
persons in 1980 to 21.1 million in 2010. This increase mirrors the
increasing prevalence of obesity. Worldwide, there is a projected
increase in the prevalence of diabetes from 382 million (8.3%) in
2013 to 592 million (10.1%) in 2035.9 Estimates of the preva-
lence in developing countries show even more marked increases,
particularly in areas where populations are rapidly adopting
Western lifestyles (Table 1).9 The increase in the prevalence of
obesity in childhood has led to the appearance of type 2 diabetes
in children and young adults, particularly those in highly sus-
ceptible ethnic groups. In the United States, prevalence of type 2
diabetes in youth (age 10e19 years) was higher in AmericanTop ten countries for number of people aged 20e79 years wit
diabetes prevalence (%) in 2013 and 2035 (b)
2013
Country No. of adults with
diabetes (millions)
a
1 China 98.4
2 India 65.1
3 USA 24.4
4 Brazil 11.9
5 Russian Federation 10.9
6 Mexico 8.7
7 Indonesia 8.5
8 Germany 7.6
9 Egypt 7.5
10 Japan 7.2
2013
Country Prevalence (%)
b
1 Tokelau 37.5
2 Federated States of
Micronesia
35.0
3 Marshall Islands 34.9
4 Kiribati 28.8
5 Cook Islands 25.7
6 Vanuatu 24.0
7 Saudi Arabia 24.0
8 Nauru 23.3
9 Kuwait 23.1
10 Qatar 22.9
Adapted from International Diabetes Federation. IDF Diabetes Atlas Sixth Edition (ww
Table 1
MEDICINE 42:12 700Indian, black and Hispanic youth compared with white youth,
and increased overall from 0.34 per 1000 (95% confidence in-
terval 0.31e0.37) in 2001 to 0.46 per 1000 (95% CI, 0.43e0.49)
in 2009.12Aetiological factorsProspective studies suggest that the main pathophysiological
defects leading to type 2 diabetes are insulin resistance and a
relative insulin secretory defect. The main aetiological risk fac-
tors are age, obesity, family history, and physical inactivity. Di-
etary risk factors have recently emerged: risk is increased by high
consumption of red and processed meat13 and sugar-sweetened
beverages,14 and reduced by intake of fruit and vegetables,15
some types of dairy products,16 and some overall dietary pat-
terns.17 Novel strategies to use quantifiable nutritional bio-
markers are paving the way for more detailed understanding of
the association between diet and diabetes. Although the herita-
bility of type 2 diabetes is high (30e70%) and more than 60
genetic variants related with diabetes risk have now been iden-
tified,18 the individual effects of genetic variants are modest, andh diabetes in 2013 and 2035 (a) and top ten countries for
2035
Country No. of adults with
diabetes (millions)
China 142.7
India 109.0
USA 29.7
Brazil 19.2
Mexico 15.7
Indonesia 14.1
Egypt 13.1
Pakistan 12.8
Turkey 11.8
Russian Federation 11.2
2035
Country Prevalence (%)
Tokelau 37.9
Federated States of
Micronesia
35.1
Marshall Islands 35.0
Kiribati 28.9
Cook Islands 25.7
Saudi Arabia 24.5
Vanuatu 24.2
Nauru 23.3
Kuwait 23.2
Qatar 22.8
w.idf.org/diabetesatlas). IDF 2013. Brussels.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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contribute little to the prediction of diabetes. Phenotype-based
risk models provide greater discrimination for diabetes, and the
addition of genotypic information adds no more than 5e10%
improvement in prediction. The current conclusion is that ge-
netic variants provide insights into biological pathways and
pathogenesis of diabetes, but not its prediction. It is likely that
interactions between the environment/lifestyle and genetic fac-
tors provide the explanation for the risk of type 2 diabetes, but
demonstrating such interaction is challenging. Encouraging
research findings have recently shown higher absolute risk of
diabetes associated with obesity at any level of genetic risk.19
Prevention and screeningPrimary preventionRandomized clinical trials in several countries have provided
evidence that, in high-risk individuals with IGT, progression to
type 2 diabetes can be reduced by intensive lifestyle intervention
with diet or physical activity, or with drug therapy using glucose-
lowering agents such as metformin.20 In addition to their clinical
effectiveness, there is now also evidence for the cost effective-
ness of these interventions. The challenges that remain are to
determine how high-risk individuals should be identified, and
how lifestyle changes of healthier diet and regular physical ac-
tivity can be sustained The evidence from randomized controlled
trials that diabetes can be prevented does not prove that inter-
vention in high-risk individuals is the most appropriate strategy
for prevention in real world settings. As in many areas of primary
prevention, high-risk approaches can be effective for the in-
dividuals included in the programmes but have a limited impact
on the public health burden of diabetes. Complementary ap-
proaches that seek to make small shifts in the population dis-
tribution of dietary and physical activity behaviours are required.
Such approaches make relatively little difference in risk at the
individual level but have a major impact on the public health
burden of diabetes when that risk reduction is summated across
large numbers of people in the population.21 The future challenge
involves finding ways of integrating high-risk and population
approaches to prevention, and balancing relative investment in
the two strategies.Secondary prevention: screeningAs it is estimated that the onset of type 2 diabetes occurs an average
of about 4e7 years before clinical diagnosis, and as a high pro-
portionof individuals exhibit evidenceof end-organdamageby that
point, screening has been proposed in the hope that early detection
and early treatment would reduce long-term burden. However
there is no definitive evidence that screening results in net benefit
and most authorities have proposed opportunistic rather than
systematic screening targeting high-risk sub-groups. Recent data
have emerged from the ADDITION-Europe, a pragmatic primary
care-based trial of intensivemultifactorial treatmentcomparedwith
routine care on cardiovascular outcomes among individuals with
screen-detected diabetes. This trial shows that:
 Screening for diabetes is feasible, and has limited short-
and long-term adverse psychological impact.
 Cardiovascular risk factors (blood pressure, cholesterol and
weight), including lifestyle behaviours (smoking), improveMEDICINE 42:12 701markedly following screen detection of diabetes, even
among those receiving routine general practice care.
 At the population level, invitation of high-risk individuals
to screening is not associated with a reduction in all-cause
or diabetes-related mortality over 10 years.22,23
Uncertainties remain concerning optimal strategies to increase
uptake of screening, to deliver care to screen-detected patients
and to manage those who screen negative but are at high risk of
diabetes and cardiovascular disease, as well as the overall cost-
effectiveness of screening programmes. Rather than screening
whole populations for diabetes, primary care teams should focus
efforts on earlier detection, lifestyle advice and intensive treat-
ment of risk factors among individuals at high risk of diabetes
and cardiovascular disease.
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